Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02008357 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,169
- Enrollment target
NCT02008357: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT02008357 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,169 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02008357, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,169 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease \[AD\]).
Primary Outcome
PACC has 4 components: Free and Cued Selective Reminding Test (0 (worst)-96 (best recall); Delayed Paragraph Recall test (Range 0 (worst)-25 (best recall); Wechsler Adult Intelligence scale: Digit Symbol Substitution Test (DSST): (ranges 0 \[none\]-91 \[best performance\]) and Mini Mental State Examination (Range 0 \[worst\] - 30 \[best performance\]). Component scores are transformed using an established normalization method into z-scores. Each of 4 component change scores is divided by baselin
Interventions
- DRUG Placebo
- DRUG Solanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,169 participants |
| Start Date | 2014-02-28 |
| Est. Completion | 2023-06-08 |
| Phase | Phase 3 |
What the finished NCT02008357 record still lists
NCT02008357 is an interventional study that assigns participants to a tested intervention. Its 1,169 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02008357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02008357 about?
NCT02008357 is a clinical study titled "Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss". The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease \[AD\]).
What is the current status of trial NCT02008357?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,169 participants. The study started on 2014-02-28. Estimated completion is 2023-06-08.
What interventions are being tested in trial NCT02008357?
The interventions under investigation include: Placebo (DRUG), Solanezumab (DRUG).
Who is sponsoring clinical trial NCT02008357?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02008357's enrollment target sits among peer trials
1,169 237th of 2000 higher than 1,764 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06469788 · 1,170 participants · NA
Testimonials and Navigation in Rheumatology
- NCT07009509 · 1,166 participants · NA
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
- NCT04275557 · 1,174 participants
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
- NCT07237048 · 1,164 participants · Phase 2
Minocycline in Stroke Study at Maimonides
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI